Novogen Limited (ADR)  

(Public, NASDAQ:NVGN)   Watch this stock  
Find more results for NVGN
5.98
+0.01 (0.12%)
Real-time:   11:50AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.95 - 6.09
52 week 1.51 - 9.50
Open 6.02
Vol / Avg. 43,639.00/1.04M
Mkt cap 97.31M
P/E     -
Div/yield     -
EPS -0.91
Shares 168.56M
Beta 0.65
Inst. own 0%
Jun 24, 2015
Novogen Ltd Ordinary Shareholders Meeting - 12:00AM EDT - Add to calendar
Mar 3, 2015
Novogen Ltd Ordinary Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -7785.26% -8700.00%
Operating margin -7785.27% -8700.00%
EBITD margin - -6600.00%
Return on average assets -132.92% -145.43%
Return on average equity -279.01% -269.02%
Employees 12 -
CDP Score - -

Address

L 1 16 - 20 Edgeworth David Ave
SYDNEY, NSW 2077
Australia
+61-2-98780088 (Phone)
+61-2-94760388 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novogen Limited, is an Australia-based biotechnology company. The Company owns two drug technology platforms. The Company targets unmet clinical needs and has therapeutic potential across cancer, degenerative disorders, autoimmune disease and regenerative medicine. The Company aims to enable cytotoxic chemotherapy to eradicate most forms of cancer. The drug technologies include: Super-Benzopyrans and Anti-Tropomyosins. Super-Benzopyrans, possess the ability to kill cancer stem cells, prevent cancer recurrence, potential to become standard of care for first-line therapy across most forms of cancer, and manageable toxicity. Anti-Tropomyosins, drug targeting cancer cell’s micro-filaments, complement the action of used drugs in oncology, and potential to become standard of care in combination with taxanes and vinca alkaloids.

Officers and directors

Graham Edmund Kelly Chairman of the Board, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Cristyn Humphreys Chief Operating Officer - Administration and Finance
Bio & Compensation  - Reuters
David Brown Chief Scientific Officer
Bio & Compensation  - Reuters
Andrew Heaton Vice President - Drug Discovery
Bio & Compensation  - Reuters
Lilischkis Kimberley Clinical & Regulatory Affairs Manager
Bio & Compensation  - Reuters
Stephen Palmer Program Director - Degenerative Diseases
Bio & Compensation  - Reuters
Justine R. Stehn Ph.D. Director - ATM Program
Bio & Compensation  - Reuters
Steven Roy Stent Coffey Non-Executive Director
Bio & Compensation  - Reuters
Peter Gunning Non-Executive Director
Bio & Compensation  - Reuters
John P. O'Connor III Non-Executive Director
Bio & Compensation  - Reuters